A health economic model of breakthrough pain

American Journal of Managed Care

Volumn 14, Issue SUPPL. 4, 2008, Pages

  Abernethy, Amy P ^a,d   Wheeler, Jane L ^a   Fortner, Barry V ^b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Scientific Affairs and Provider Services   (United States)

^c UNIVERSITY OF MEMPHIS   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; FENTANYL; FENTANYL CITRATE; IBUPROFEN; MORPHINE; OPIATE; OXYCODONE;

BREAKTHROUGH PAIN; CHRONIC PAIN; COST BENEFIT ANALYSIS; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANALGESICS, OPIOID; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; MULTIPLE MYELOMA; PAIN;

EID: 44649170982     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence, and characteristics. Pain. 1990;41:273-281.
2. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 1: assessment. Pharm Ther. 2005;30:296-301.
3. Svendsen KB, Andersen S, Amason S, et al. Breakthrough pain in malignant and non malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain. 2005;9:195-206.
4. Du Pen SL, Du Pen AR, Polissar N, et al. Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial. J Clin Oncol. 1999;17:361-370.
5. McCarberg BH. The treatment of breakthrough pain. Pain Med. 2007;8:S8-S13.
6. Abernethy AP, Samsa GP, Matchar DB. A clinical decision and economic analysis model of cancer pain management. Am J Manag Care. 2003;9:651-664.
7. Payne R. Recognition and diagnosis of breakthrough pain. Pain Med. 2007;8:S3-S7.
8. Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3:38-44.
9. Taylor DR, Webster LR, Chun SY, et al. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med. 2007;8:281-288.
10. Jolicoeur LM, Jones-Grizzle AJ, Boyer JG. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm. 1992;49:1741-1747.
11. Sule NS, Nerurkar RP, Kamath SA. Pharmacoeconomics. J Assoc Physicians India. 2002;50:1057-1062.
12. Ferrell BR, Griffith H. Cost issues related to pain management: report from the Cancer Pain Panel of the Agency for Health Care Policy and Research. J Pain Symptom Manag. 1994;9:221-234.
13. Chandler S, Payne R. Economics of unrelieved cancer pain. Am J Hosp Palliat Care. 1998;15:223-226.
14. Fortner BV, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manag. 2003;25:9-18.
15. Abernethy AP, Hemdon JE, Day JD, et al. E-tablets to collect research-quality patient-reported data. Poster presented at the American Society of Clinical Oncology 43rd Annual Meeting. Chicago, IL. June 2, 2007.
16. Hatten AL, Gatchel RJ, Polatin PB, Stowell AW. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years. Clin J Pain. 2006;22:700-711.
17. Rivero-Arias O, Campbell H, Gray A, et al. Surgical stabilisation of the spine compared with a programme of intensive rehabilitation for the management of patients with chronic low back pain: cost utility analysis based on a randomized controlled trial. BMJ. 2005; 330:1239.
18. Tarride JE, Gordon A, Vera-Llonch M, Dukes E, Rousseau C. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther. 2006;28: 1922-1934.
19. Rahimi SY, Vender JR, Macomson SD, French A, Smith JR, Alleyne CH Jr. Postoperative pain management after craniotomy: evaluation and cost analysis. Neurosurgery. 2006;59:852-857.
20. Williams BA, Kentor ML, Vogt MT, et al. Economics of nerve block pain management after anterior cruciate ligament reconstruction: potential hospital cost savings via associated postanesthesia care unit bypass and same-day discharge. Anesthesiology. 2004;100: 697-706.
21. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17:197-210.
22. Fortner BV, Okon TA, Ashley J, et al. The Zero Acceptance of Pain (ZAP) Quality Improvement Project: evaluation of pain severity, pain interference, global quality of life, and pain-related costs. J Pain Symptom Manage. 2003;25:334-343.
23. Burton AW, Driver LC, Mendoza TR, Syed G. Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises: a retrospective case series. Clin J Pain. 2004;20:195-197.